Lazard Asset Management
AQST icon

Lazard Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Lazard Asset Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,112
Closed -$124K – 2223
2024
Q1 		$124K Buy
29,112
+15,601
+115% +$51.9K ﹤0.01% 1462
2023
Q4 		$27K Buy
13,511
+12,745
+1,664% +$22.5K ﹤0.01% 2023
2023
Q3 		$1K Buy
+766
New +$1.32K ﹤0.01% 2210

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lazard Asset Management's AQST Position: Q2 2024 in Review

Lazard Asset Management sold out of Aquestive Therapeutics (AQST) in Q2 2024, closing a stake of 29,112 shares — an estimated $124K sold.

Lazard Asset Management first reported a position in AQST in Q3 2023 and held it in 3 quarters. The position peaked at $124K in Q1 2024. 97 funds tracked by Wall St. Rank hold AQST as of Q2 2024.

  • Lazard Asset Management reported no remaining Aquestive Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lazard Asset Management sold 29,112 Aquestive Therapeutics shares in Q2 2024, an estimated $124K.
  • Lazard Asset Management first reported a position in Aquestive Therapeutics in Q3 2023 and held it in 3 quarters.
  • Lazard Asset Management's Aquestive Therapeutics position peaked at $124K in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2024.

Based on Lazard Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.